Illumina Archives - San Diego Biotechnology Connection

Thermo Fisher acquiring Life Technologies — Illumina merger nex

Embryo genetic test doubles rate of one ‘in vitro fertilization’ baby

Brown University study: Sequenom Down syndrome test highly accurate

Scientists scoff at 8-track tape Illumina jab as Roche’s buyout fails

Illumina fending off Roche buyout offer, investors betting on higher o

Test for Down syndrome & trisomies gives wrenching choices

Illumina adopts poison-pill defense against Roche takeover bid

Stock Daily Change

Biotech Events in San Diego

@SDBiotech

San Diego Biotechnology Connection

April 26, 2013 no comments

By Rex Graham Thermo Fisher Scientific’s (TMO) decision to acquire Life Technologies for $13.6 billion will create a sequencing and diagnostics juggernaut that will position Fisher to become a domina Read More

Human blastocysts, Robert Shabanowitz, Gesinger Medical Center, San Diego Biotechnology Connection

October 22, 2012 no comments

By Rex Graham Millions of infertile women will soon get the biggest baby boost in a generation from preimplantation genetic diagnosis (PGD), which identifies their healthiest embryos at in vitro fert Read More

Blood test for Down syndrome, NIH, San Diego Biotechnology Connection

May 21, 2012 no comments

By Rex Graham In a large international study of a controversial new Down syndrome test, a team led by two Brown University professors of laboratory medicine and a human-genetics lab at UCLA verified Read More

DNA sequencing, NIGMS, NIH, San Diego Biotechnology Connection

April 23, 2012 no comments

By Rex Graham After its unsolicited $51-per-share buyout bid for San Diego-based Illumina (ILMN) failed, the Swiss pharmaceutical giant Roche Holding AG (ROG) said it would seek better opportunities Read More

March 29, 2012 no comments

Illumina, a San Diego-based biotech company is fending off a Roche buyout offer, advising stockholders not to sell despite the Swiss pharmaceutical giant’s offer of $51 per share, up from its earlier Read More

Baby Kyle with Mom, Trisomy 18 Foundation, San Diego Biotechnology Connection

February 15, 2012 no comments

By Rex Graham In a large independent, international study of an innovative new blood test for Down syndrome and other chromosomal disorders, a team led by two Brown University professors of laborator Read More

Joseph R. Eicher, Salk Institute for Biological Studies, San Diego Biotechnology Connection

January 26, 2012 no comments

By Rex Graham The board of Illumina, Inc., on Jan. 26 announced a poison-pill defense against a Roche takeover bid. Roche’s offer of $44.50 per share for all shares of Illumina common stock, or $5.7 Read More

ADMP	0.668	+0.06
AEMD	0.105	-0.0038
AHRO	0.73	0.00
AIMM	0.0035	0.00
AMGN	104.24	+2.06
ANX	0.733	0.00
APRI	3.41	+0.06
ARNA	7.99	+0.03
ATEC	1.95	+0.03
AVNR	3.27	-0.07
AVTO	0.005	0.00
AXMP	0.012	0.00
AXRX	0.16	0.00
CADX	6.99	+0.12
CELG	123.50	+0.38
CORX	0.04	-0.01
CXM	0.091	+0.001
CYTX	2.54	+0.04
CYTR	2.42	0.00
DRAD	2.44	+0.04
DXCM	21.13	-0.11
ENTB	0.002	-0.0004
FOLD	3.46	+0.05
HALO	7.59	+0.02
HRBR	0.1887	-0.0003
IAGXQ	0.14	+0.03
ILMN	72.58	-0.50
IMBI	0.028	0.00
ISCO	0.30	+0.023
ISIS	20.81	+0.35
IVRO	0.017	-0.0028
LGND	27.74	+0.17
LIFE	73.68	+0.11
LJPC	0.075	-0.0004
LPTN	4.90	-0.05
MCK	118.41	+0.39
MEDS	1.20	0.00
MEIP	8.48	-0.06
MLPH	0.018	-0.002
MNKD	5.36	+0.05
MNOV	3.18	-0.24
MRIC	1.18	0.00
NAII	4.68	-0.07
NBIX	12.06	+0.05
NRDCQ	0.0001	0.00
NUXP	0.0016	0.00
ONCS	0.3205	-0.0035
OPTR	14.43	-0.27
OREX	6.11	+0.09
PCRX	28.84	+0.40
PFE	28.78	+0.08
QDEL	22.65	-0.20
RHHBY	64.71	+1.18
RMD	50.08	+0.10
SNTS	22.30	+0.20
SQNM	4.06	-0.05
TSRX	7.77	-0.11
VOLC	16.74	+0.08
VRX	75.53	+0.15
VRNM	2.15	-0.09
VVUS	13.16	+0.18
ZGNX	1.52	-0.05

2013-05-21 15:57

Trius Therapeutics: New, Positive Dimension For Investment Outlook http://t.co/rcVXC57kkN $CBST $TEVA $TSRX
8 days ago
Retweet
@ilus_art Gorgeous way to celebrate art, biology and cells.
16 days ago
Retweet
Trius Therapeutics releases persuasive safety study of potent new antibiotic against MRSA #superbug. http://t.co/uRBiPHj14U
22 days ago
Retweet
Halozyme initiates Phase 2 trial of drug to treat stage 4 pancreatic cancer. http://t.co/U9cjxGbtIL
28 days ago
Retweet
Illumina’s stronger than expected revenue up 21% sends shares up 13%. http://t.co/qviU0MYLQ3
28 days ago
Retweet
Trius presenting clinical-trial results Apr. 27 http://t.co/MCFeBYi57w on tedizolid, a potent MRSA antibiotic. http://t.co/myB421ZD2n
28 days ago
Retweet
After Thermo Fisher Scientific buys Life Technologies, sequencing leader Illumina may finally sell. http://t.co/F92ndBP0z2
36 days ago
Retweet
http://t.co/y8xbsAQ4q8
61 days ago
Retweet
FDA reviewing diabetes drugs causing pancreas precancers. Affected: Lilly, Merck, Novo Nordisk, Bristol-Myers. http://t.co/2dPyRAYLsc
67 days ago
Retweet

21 Events on May 21, 2013 Rising Above the Storm by Investing in Science and Technology Starts: 11:00 am Ends: May 21, 2013 - 12:00 pm Location: Scripps Research Inst. - Molecular Biology Building 2N, Committee Lecture Hall Description: Frontiers In Microbial Pathogenesis Symposium Speaker: Rino Rappuoli, Ph.D., Global Head of Vaccine Research, Novartis Vaccines & Diagnostics, Siena, Italy Read More: <a href="http://onlinelibrary.wiley.com/doi/10.1111/nyas.12046/abstract?deniedAccessCustomisedMessage=&userIsAuthenticated=false">link</a> More details...

23 Events on May 23, 2013 Studies Toward the Synthesis of Antitumor Natural Products Starts: 4:00 pm Ends: May 23, 2013 - 5:00 pm Location: Scripps Research Inst. - Green Hospital Building, Valerie Timken Amphitheater Description: Distinguished Lecture Series Speaker: John A. Porco, Ph.D., Professor, Department of Chemistry, Boston University Read More: <a href="http://pubs.rsc.org/en/content/articlelanding/2013/np/c3np20122h">link</a> More details...

The share price of Trius Therapeutics (TSRX) has rebounded almost fully from its 10 percent dip in the New Year that was triggered by its public offering of 7 million shares; however, uncertainty about the company’s lead investigational drug is a lingering February hangover. Small investors face a dilemma: should they dump their diluted shares, double down? Our story explains why we recommend doubling down: http://sandiegobiotechnology.com/topics/5733/trius-dump-or-double-down-on-maker-of-mrsa-antibiotic/
99 days ago
A Glaxo Smith Kline genital herpes vaccine recently flopped in a large clinical trial, but “next generation” genital herpes vaccines by Genocea Biosciences, Agenus, Inc., and San Diego-based Vical, Inc., offer new hope. http://sandiegobiotechnology.com/topics/5600/glaxo-genital-herpes-vaccine-flops-but-genocea-a-buy-in-vaccine-space/
159 days ago
The Dow was off 1.82 percent, down 243.36 points to 13,102.53 at the close of trading Oct. 23 amid disappointing earnings reports. But 11 publicly traded San Diego biotechs gained for the day. https://sandiegobiotechnology.com/topics/5443/eleven-san-diego-biotech-stocks-rise-amid-tuesday-plunge-in-dow/
210 days ago
Millions of infertile women will soon get the biggest baby boost in a generation from preimplantation genetic diagnosis (PGD), which identifies their healthiest embryos at in vitro fertilization (IVF) clinics. These blastocysts, embryos with 50-150 cells, are at a very favorable stage for implantation and pregnancy. The inner cell mass will give rise to the actual cells of the fetus. The other cells that surround and protect the inner cell mass give rise to the fetal part of the placenta. Photo: Robert Shabanowitz, Gesinger Medical Center
212 days ago
It’s more than a 5-hour energy jolt. Cardium Therapeutics’ purchase of To Go Brands and its nationwide marketing network will give the San Diego biotech company a permanent sales boost for its own nutritional supplements -- and a larger piece of the $30 billion supplements market. https://sandiegobiotechnology.com/topics/5393/cardium-boosts-energy-supplement-sales-with-national-marketing-muscle/
231 days ago